Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium and the entry of biosimilars will make treatment decisions increasingly complex, especially in the absence of clear differentiation between novel drugs and between drugs from the same class. Despite being listed in the NRDL, biologics still cost more than traditional treatment options, including topicals and conventional systemics (e.g., methotrexate, acitretin). Thus, although improving rapidly, China’s market access and reimbursement environment still limits the use of these drugs to later lines (i.e., patients who do not respond to traditional treatments). In this report, we explore the impact of unmet needs, pricing, coverage, and regulatory reforms in China on the success of current and future players in this highly lucrative market.
Questions answered
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.